IL149534A0 - Preparation of 3-substituted-4-arylquinolin-2-one derivatives - Google Patents

Preparation of 3-substituted-4-arylquinolin-2-one derivatives

Info

Publication number
IL149534A0
IL149534A0 IL14953400A IL14953400A IL149534A0 IL 149534 A0 IL149534 A0 IL 149534A0 IL 14953400 A IL14953400 A IL 14953400A IL 14953400 A IL14953400 A IL 14953400A IL 149534 A0 IL149534 A0 IL 149534A0
Authority
IL
Israel
Prior art keywords
arylquinolin
derivatives
substituted
preparation
Prior art date
Application number
IL14953400A
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of IL149534A0 publication Critical patent/IL149534A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
IL14953400A 1999-12-01 2000-11-28 Preparation of 3-substituted-4-arylquinolin-2-one derivatives IL149534A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16834699P 1999-12-01 1999-12-01
PCT/US2000/032382 WO2001040191A1 (en) 1999-12-01 2000-11-28 Preparation of 3-substituted-4-arylquinolin-2-one derivatives

Publications (1)

Publication Number Publication Date
IL149534A0 true IL149534A0 (en) 2002-11-10

Family

ID=22611149

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14953400A IL149534A0 (en) 1999-12-01 2000-11-28 Preparation of 3-substituted-4-arylquinolin-2-one derivatives

Country Status (12)

Country Link
US (1) US6353119B1 (en)
EP (1) EP1233947A4 (en)
JP (1) JP2003515593A (en)
KR (1) KR20020058066A (en)
AU (1) AU769481B2 (en)
CA (1) CA2393012A1 (en)
HK (1) HK1048633A1 (en)
HU (1) HUP0203364A3 (en)
IL (1) IL149534A0 (en)
MX (1) MXPA02005470A (en)
TW (1) TW562799B (en)
WO (1) WO2001040191A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6939968B2 (en) 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
WO2004099442A2 (en) * 2003-05-06 2004-11-18 University Hospital Of Basel Kcnma1 as a therapeutic target in cancer treatment
US7179920B2 (en) * 2003-10-14 2007-02-20 Bristol-Myers Squibb Company 3-thia-4-arylquinolin-2-one derivatives
US7132542B2 (en) 2003-10-14 2006-11-07 Bristol-Myers Squibb Company Compounds for the treatment of male erectile dysfunction
US7049309B2 (en) * 2003-10-14 2006-05-23 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one potassium channel modulators
US7151180B2 (en) * 2003-10-14 2006-12-19 Bristol-Myers Squibb Company Potassium channel modulators
US7145013B2 (en) * 2003-10-14 2006-12-05 Bristol-Myers Squibb Company 3-thia-4-arylquinolin-2-one derivatives
US7002015B2 (en) * 2003-10-14 2006-02-21 Bristol-Myers Squibb Company 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091428A (en) * 1987-04-24 1992-02-25 Syntex Pharmaceuticals, Ltd. Substituted imidazolyl-alkyl-piperazine and -diazepine derivatives
US5200422A (en) 1990-09-24 1993-04-06 Neurosearch A/S Benzimidazole derivatives, their preparation and use
US5234947A (en) 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
TW504504B (en) 1996-11-26 2002-10-01 Bristol Myers Squibb Co 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators
AU8534198A (en) * 1997-08-05 1999-03-01 Novo Nordisk A/S Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use
AU742452B2 (en) 1997-08-28 2002-01-03 Bristol-Myers Squibb Company 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators
NZ510987A (en) * 1998-12-04 2004-02-27 Bristol Myers Squibb Co 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators

Also Published As

Publication number Publication date
KR20020058066A (en) 2002-07-12
HUP0203364A2 (en) 2003-02-28
HK1048633A1 (en) 2003-04-11
EP1233947A1 (en) 2002-08-28
CA2393012A1 (en) 2001-06-07
HUP0203364A3 (en) 2005-11-28
WO2001040191A1 (en) 2001-06-07
MXPA02005470A (en) 2003-01-28
TW562799B (en) 2003-11-21
EP1233947A4 (en) 2003-01-02
US6353119B1 (en) 2002-03-05
JP2003515593A (en) 2003-05-07
AU2048701A (en) 2001-06-12
AU769481B2 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
EG23817A (en) 4-Phenyl-pyridine derivatives
PL351261A1 (en) Derivatives of indigoid bisindoles
GC0000183A (en) 3-Phenyl-pyridine derivatives
GC0000338A (en) 5-Phenyl-pyrimidine derivatives
PL352296A1 (en) Crystalline derivatives of 1-methylocarbapeneme
HK1044940A1 (en) Isoxazolecarboxamide derivatives
EG23070A (en) Novel propargylether derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
EG22530A (en) Preparation of substituted piperidin-4-ones
AU2982000A (en) Preparation of 9-hydrocarbyl-9-phosphabicyclononanes
IL149534A0 (en) Preparation of 3-substituted-4-arylquinolin-2-one derivatives
HUP0204217A3 (en) Novel a-500359 derivatives
GB9925880D0 (en) B-Carboline derivatives
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
EP1218407A4 (en) Uses of kappa-conotoxin pviia
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
IL144693A0 (en) Preparation of carvone
PL350963A1 (en) Use of arylalkanoylpyridazines
HUP0201610A3 (en) Derivatives of 4'-demycarosyl-8a-aza-8a-homotylosin
GB9929044D0 (en) Preparation of bait
HU9904011D0 (en) Novel salts of dipeptid derivatives
SI1301469T1 (en) Preparation of 4-thioalkylbromobenzene derivatives
IL146505A0 (en) Methods for the preparation of tetrahydroisoquinolinephenol derivatives
PL340617A1 (en) Derivatives of 2-acylpyridine